Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23 pseudogene 2 (RPL23P2) is a processed pseudogene of the functional ribosomal protein gene RPL23, which encodes a component of the 60S ribosomal subunit[1][4][5][8]. Pseudogenes like RPL23P2 arise from reverse transcription and genomic insertion of mRNA from functional ribosomal protein genes, but they typically do not produce functional proteins due to disabling mutations, truncations, or other sequence disruptions[4]. The RPL23P2 gene does not encode a protein or have known direct biological activity and is not considered a drug target or therapeutic receptor/enzyme/transporter. Some studies have explored the expression of ribosomal protein pseudogenes in cancer, including the association of similar pseudogenes (e.g., RPL23AP53) with melanoma prognosis and immune cell infiltration, but no direct therapeutic or biomarker role is established for RPL23P2 itself[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23 pseudogene 2 (RPL23P2).